The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD), which is strongly associated with metabolic syndrome, is increasingly a major cause of hepatic disorder. Dipeptidyl peptidase (DPP)-4 inhibitors, anti-diabetic agents, are expected to be effective for the treatment of NAFLD. In the present study, we established a novel NAFLD model mouse using monosodium glutamate (MSG) and a high-fat diet (HFD) and investigated the effects of a DPP-4 inhibitor, teneligliptin, on the progression of NAFLD. Male MSG/HFD-treated mice were divided into two groups, one of which received teneligliptin in drinking water. Administration of MSG and HFD caused mice to develop severe fatty changes in the liver, but teneligliptin treatment improved hepatic steatosis and inflammation, as evaluated by the NAFLD activity score. Serum alanine aminotransferase and intrahepatic triglyceride levels were significantly decreased in teneligliptin-treated mice (p < 0.05). Hepatic mRNA levels of the genes involved in de novo lipogenesis were significantly downregulated by teneligliptin (p < 0.05). Moreover, teneligliptin increased hepatic expression levels of phosphorylated AMP-activated protein kinase (AMPK) protein. These findings suggest that teneligliptin attenuates lipogenesis in the liver by activating AMPK and downregulating the expression of genes involved in lipogenesis. DPP-4 inhibitors may be effective for the treatment of NAFLD and may be able to prevent its progression to non-alcoholic steatohepatitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A liver-derived secretory protein, selenoprotein P, causes insulin resistance
Misu, H., Takamura, T., Takayama, H., Hayashi, H., Matsuzawa-Nagata, N., Kurita, S., Ishikura, K., Ando, H., Takeshita, Y., Ota, T., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.09.015 · Cited by 583
Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532 · cited 2×
“Furthermore, in the feeding state, serum incretin levels appear to be higher in the teneligliptin-treated group, and it can be suspected that serum glucose metabolism was relatively dependent on the functions of incretins, including the functions that induce insulin secretion from the pancreas and enhance the insulin…”
BackgroundSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Trevaskis, J. L., Griffin, P. S., Wittmer, C., Neuschwander-Tetri, B. A., Brunt, E. M., Dolman, C. S., Erickson, M. R., Napora, J., Parkes, D. G., & Roth, J. D. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00476.2011 · Cited by 277 · cited 1×
“Moreover, several studies have revealed the potential roles of incretin-based therapies, including DPP-4 inhibitors and GLP-1 receptor agonists, in the treatment of NAFLD [18,19].”
BackgroundLee, J., Hong, S.-W., Chae, S. W., Kim, D. H., Choi, J. H., Bae, J. C., Park, S. E., Rhee, E.-J., Park, C.-Y., Oh, K.-W., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031394 · Cited by 157
Dipeptidyl peptidase IV (DDP IV) in NASH patients
Balaban, Y. H., Korkusuz, P., Simsek, H., Gokcan, H., Gedikoglu, G., Pinar, A., Hascelik, G., Asan, E., Hamaloglu, E., & Tatar, G. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31905-2 · Cited by 125
Choi, H. Y., Hwang, S. Y., Lee, C. H., Hong, H. C., Yang, S. J., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., et al. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.1.63 · Cited by 111 · cited 1×
“[31] suggested this reciprocal causality by demonstrating that the serum level of selenoprotein P, which is a liver-derived secretory protein and which is higher in subjects with NAFLD [32], causes insulin resistance.”
Background
Research works printed but not linked: 42
- Calle, 2003, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N. Engl. J. Med., 348, 1625, 10.1056/NEJMoa021423 · DOI · Paper page
- Chalasani, 2012, The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association, Hepatology, 55, 2005, 10.1002/hep.25762 · DOI · Paper page
- Sass, 2005, Nonalcoholic fatty liver disease: A clinical review, Dig. Dis. Sci., 50, 171, 10.1007/s10620-005-1267-z · DOI · Paper page
- Bacon, 1994, Nonalcoholic steatohepatitis: An expanded clinical entity, Gastroenterology, 107, 1103, 10.1016/0016-5085(94)90235-6 · DOI · Paper page
- Kim, 2008, Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome, Clevel. Clin. J. Med., 75, 721, 10.3949/ccjm.75.10.721 · DOI · Paper page
- Vanni, 2010, From the metabolic syndrome to NAFLD or vice versa?, Dig. Liver Dis., 42, 320, 10.1016/j.dld.2010.01.016 · DOI · Paper page
- Ascha, 2010, The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, Hepatology, 51, 1972, 10.1002/hep.23527 · DOI · Paper page
- Marchesini, 1999, Association of nonalcoholic fatty liver disease with insulin resistance, Am. J. Med., 107, 450, 10.1016/S0002-9343(99)00271-5 · DOI · Paper page
- Sanyal, 2002, Aga technical review on nonalcoholic fatty liver disease, Gastroenterology, 123, 1705, 10.1053/gast.2002.36572 · DOI · Paper page
- Shimizu, 2011, Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice, BMC Cancer, 11, 281, 10.1186/1471-2407-11-281 · DOI
- Shimizu, 2011, Preventive effects of (−)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice, Cancer Prev. Res., 4, 396, 10.1158/1940-6207.CAPR-10-0331 · DOI
- Ohno, 2015, Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+Leprdb/+Leprdb mice, PLoS ONE, 10, e0124081, 10.1371/journal.pone.0124081 · DOI
- Lonardo, 2015, Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome, Dig. Liver Dis., 47, 181, 10.1016/j.dld.2014.09.020 · DOI · Paper page
- Zhang, 2015, Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified bayesian network in a chinese population, BMJ Open, 5, e008204, 10.1136/bmjopen-2015-008204 · DOI
- Aschner, 2006, Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes, Diabetes Care, 29, 2632, 10.2337/dc06-0703 · DOI · Paper page
- Schweizer, 2007, Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes, Diabetes Res. Clin. Pract., 76, 132, 10.1016/j.diabres.2006.12.009 · DOI · Paper page
- Klein, 2014, Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis, Med. Mol. Morphol., 47, 137, 10.1007/s00795-013-0053-9 · DOI
- Schuppan, 2010, The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis, Liver Int., 30, 795, 10.1111/j.1478-3231.2010.02264.x · DOI
- Yilmaz, 2009, Dipeptidyl peptidase IV inhibitors: Therapeutic potential in nonalcoholic fatty liver disease, Med. Sci. Res., 15, HY1-5
- Collison, 2012, Interactive effects of neonatal exposure to monosodium glutamate and aspartame on glucose homeostasis, Nutr. Metabol., 9, 58, 10.1186/1743-7075-9-58 · DOI
- Nagata, 2006, Type 2 diabetes mellitus in obese mouse model induced by monosodium glutamate, Exp. Anim. Jpn. Assoc. Lab. Anim. Sci., 55, 109
- Jasso, 2011, Monosodium glutamate neonatal intoxication associated with obesity in adult stage is characterized by chronic inflammation and increased mRNA expression of peroxisome proliferator-activated receptors in mice, Basic Clin. Pharmacol. Toxicol., 108, 406, 10.1111/j.1742-7843.2011.00671.x · DOI
- Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
- Li, 2011, AMPK phosphorylates and inhibits Srebp activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice, Cell Metabol., 13, 376, 10.1016/j.cmet.2011.03.009 · DOI · Paper page
- Serviddio, 2013, Free radical biology for medicine: Learning from nonalcoholic fatty liver disease, Free Radic. Biol. Med., 65, 952, 10.1016/j.freeradbiomed.2013.08.174 · DOI · Paper page
- Blaslov, 2014, Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease, World J. Gastroenterol., 20, 7356, 10.3748/wjg.v20.i23.7356 · DOI · Paper page
- Shimizu, 2011, Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J- +leprdb/+leprdb mice, Cancer Prev. Res., 4, 128, 10.1158/1940-6207.CAPR-10-0163 · DOI
- Musso, 2009, Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD), Progress Lipid Res., 48, 1, 10.1016/j.plipres.2008.08.001 · DOI · Paper page
- Higuchi, 2008, Liver X receptor in cooperation with Srebp-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease, Hepatol. Res., 38, 1122, 10.1111/j.1872-034X.2008.00382.x · DOI · Paper page
- Kern, 2012, Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity, PLoS ONE, 7, e38744, 10.1371/journal.pone.0038744 · DOI
- Singh, 2015, Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis, Hepatology, 62, 1417, 10.1002/hep.27999 · DOI · Paper page
- Shirakami, Y., Shimizu, M., Kubota, M., Ohno, T., Kochi, T., Nakamura, N., Sumi, T., Tanaka, T., Moriwaki, H., and Seishima, M. (2015). Pentoxifylline prevents nonalcoholic steatohepatitis-related liver pre-neoplasms by inhibiting hepatic inflammation and lipogenesis. Eur. J. Cancer Prev. · doi:10.1097/cej.0000000000000172
- Hardie, 2012, Ampk: A nutrient and energy sensor that maintains energy homeostasis, Nat. Rev. Mol. Cell Biol., 13, 251, 10.1038/nrm3311 · DOI · Paper page
- Viollet, 2007, Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders, Diabetes Metab., 33, 395, 10.1016/j.diabet.2007.10.004 · DOI · Paper page
- Zvibel, 2011, Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase, J. Hepatol., 54, 1214, 10.1016/j.jhep.2010.09.032 · DOI · Paper page
- Samson, 2013, Potential of incretin-based therapies for non-alcoholic fatty liver disease, J. Diabetes Complicat., 27, 401, 10.1016/j.jdiacomp.2012.12.005 · DOI
- Boschmann, 2009, Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients, J. Clin. Endocrinol. Metab., 94, 846, 10.1210/jc.2008-1400 · DOI · Paper page
- Shimizu, 2009, Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice, Clin. Cancer Res., 15, 3068, 10.1158/1078-0432.CCR-08-2093 · doi:10.1158/1078-0432.ccr-08-2093
- Primer Blast, Available online: http://www.ncbi.nlm.nih.gov/tools/primer-blast/.
- Folch, 1957, A simple method for the isolation and purification of total lipides from animal tissues, J. Biol. Chem., 226, 497, 10.1016/S0021-9258(18)64849-5 · DOI · Paper page
- Iwasa, 2010, Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice, Cancer Sci., 101, 460, 10.1111/j.1349-7006.2009.01402.x · DOI · Paper page
- Miyazaki, 2012, Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism, Mol. Med. Rep., 5, 729
Cited by
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Lu, W., Mei, J., Yang, J., Wu, Z., Liu, J., Miao, P., Chen, Y., Wen, Z., Zhao, Z., Kong, H., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117601 · Cited by 65
Liu, H., Xiang, H., Zhao, S., Sang, H., Lv, F., Chen, R., Shu, Z., Chen, A. F., Chen, S., & Lu, H. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13975 · Cited by 52
Metadata
- Authors
- Ideta, T., Shirakami, Y., Miyazaki, T., Kochi, T., Sakai, H., Moriwaki, H., & Shimizu, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-12-08
- Volume
- 16
- Issue
- 12
- Pages
- 29207-29218
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2190193027
- Cited by
- 58
- References
- 7
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. https://app.cochat.ai/papers/10.3390/ijms161226156
- The paper
- Ideta, T., Shirakami, Y., Miyazaki, T., Kochi, T., Sakai, H., Moriwaki, H., & Shimizu, M. (2015). The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms161226156
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.